Japan Pharmas Seeing Lowest Stock Prices In Industry History
This article was originally published in PharmAsia News
Executive SummaryJapanese pharmaceutical companies are experiencing some of the lowest stock values in the history of the industry, led by Takeda Pharmaceutical and Astellas Pharma in share-price plunges. The Japan drop is sharing the fate of U.S. and European competitors as drug makers face government cutbacks in medical expenses and patents expire for some key products. Pharmas in developed countries are beginning to focus their attention more on emerging markets where incomes are increasing, but Japanese pharmas trail in that switch. (Click here for more - a subscription may be required
You may also be interested in...
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.
Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.